uniQure to Announce First Quarter 2025 Financial Results
uniQure (NASDAQ: QURE) has announced it will report its first quarter 2025 financial results on Friday, May 9, 2025, before market open. The company will host its inaugural quarterly earnings conference call at 8:30 a.m. ET on the same day. This initiative to begin regular earnings calls comes as uniQure advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, aiming to enhance engagement with the investment community.
The event will be accessible via webcast through uniQure's website, with a 90-day replay available afterward. Phone participants must pre-register through an online form to receive dial-in details and are advised to join 15 minutes before the start time.
uniQure (NASDAQ: QURE) ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 venerdì 9 maggio 2025, prima dell'apertura del mercato. La società terrà la sua prima conferenza trimestrale sugli utili alle 8:30 ET dello stesso giorno. Questa iniziativa di avviare chiamate regolari sugli utili nasce mentre uniQure avanza nel suo portafoglio e nel progetto AMT-130 verso la presentazione di una BLA e una possibile commercializzazione, con l'obiettivo di migliorare il coinvolgimento con la comunità degli investitori.
L'evento sarà accessibile in webcast tramite il sito web di uniQure, con una replica disponibile per 90 giorni successivi. I partecipanti telefonici devono preregistrarsi tramite un modulo online per ricevere i dettagli di accesso e sono invitati a collegarsi 15 minuti prima dell'inizio.
uniQure (NASDAQ: QURE) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el viernes 9 de mayo de 2025, antes de la apertura del mercado. La compañía llevará a cabo su primera llamada trimestral de resultados a las 8:30 a.m. ET ese mismo día. Esta iniciativa de comenzar llamadas regulares de resultados surge mientras uniQure avanza en su cartera y en AMT-130 hacia la presentación de una BLA y una posible comercialización, con el objetivo de fortalecer la relación con la comunidad inversora.
El evento será accesible mediante webcast a través del sitio web de uniQure, con una repetición disponible durante 90 días después. Los participantes telefónicos deben preregistrarse mediante un formulario en línea para recibir los detalles de acceso y se recomienda conectarse 15 minutos antes del inicio.
uniQure (NASDAQ: QURE)는 2025년 1분기 재무 결과를 2025년 5월 9일 금요일 시장 개장 전 발표할 예정입니다. 회사는 같은 날 오전 8:30 ET에 첫 분기 실적 컨퍼런스 콜을 개최합니다. 정기적인 실적 발표 콜을 시작하는 이번 조치는 uniQure가 파이프라인과 AMT-130을 BLA 제출 및 잠재적 상용화 단계로 진전시키면서 투자자 커뮤니티와의 소통을 강화하기 위한 것입니다.
이 행사는 uniQure 웹사이트를 통해 웹캐스트로 시청할 수 있으며, 이후 90일간 다시보기 서비스가 제공됩니다. 전화 참가자는 온라인 양식을 통해 사전 등록해야 접속 정보를 받을 수 있으며, 시작 15분 전에 접속할 것을 권장합니다.
uniQure (NASDAQ : QURE) a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le vendredi 9 mai 2025, avant l'ouverture des marchés. La société organisera sa première conférence téléphonique trimestrielle à 8h30 ET le même jour. Cette initiative de lancer des appels réguliers sur les résultats intervient alors qu'uniQure fait progresser son pipeline et AMT-130 vers un dépôt de BLA et une possible commercialisation, dans le but de renforcer l'engagement auprès de la communauté des investisseurs.
L'événement sera accessible en webcast via le site internet d'uniQure, avec une rediffusion disponible pendant 90 jours après. Les participants par téléphone doivent s'inscrire à l'avance via un formulaire en ligne pour recevoir les détails d'accès et sont invités à se connecter 15 minutes avant le début.
uniQure (NASDAQ: QURE) hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Freitag, den 9. Mai 2025, vor Börsenbeginn zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr ET seine erste Quartalskonferenz zur Ergebnisbekanntgabe abhalten. Diese Initiative, regelmäßige Ergebnisgespräche zu beginnen, erfolgt, während uniQure seine Pipeline und AMT-130 auf eine BLA-Einreichung und mögliche Kommerzialisierung vorantreibt, um die Einbindung der Investment-Community zu verbessern.
Die Veranstaltung ist über einen Webcast auf der Website von uniQure zugänglich, mit einer 90-tägigen Wiederholung danach. Telefonische Teilnehmer müssen sich vorab über ein Online-Formular registrieren, um Einwahldaten zu erhalten, und werden gebeten, 15 Minuten vor Beginn beizutreten.
- None.
- None.
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. If you are joining the conference call, please dial in 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
| uniQure Contacts: | |
| FOR INVESTORS: | FOR MEDIA: |
| Chiara Russo | Tom Malone |
| Direct: 617-306-9137 | Direct: 339-970-7558 |
| Mobile: 617-306-9137 | Mobile: 339-223-8541 |
| c.russo@uniQure.com | t.malone@uniQure.com |
FAQ
When will uniQure (QURE) report Q1 2025 earnings?
What time is uniQure's Q1 2025 earnings call?
Why is uniQure starting quarterly earnings calls in Q1 2025?
How can investors access uniQure's Q1 2025 earnings call?
